Actively Recruiting
Phase 2 Study of Camrelizumab SHR-1210 Treatment for Adults with Recurrent Primary Central Nervous System Lymphoma
Led by Beijing Sanbo Brain Hospital · Updated on 2024-10-15
21
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Primary Central Nervous System Lymphoma PCNSL is a rare type of non-Hodgkin lymphoma that affects the brain, spinal cord, eyes, and surrounding membranes. Treating recurrent PCNSL is difficult, and there is no standard approach accepted worldwide. This research aims to assess the effectiveness and safety of camrelizumab, a programmed cell death 1 PD-1 inhibitor, in patients whose PCNSL has returned after initial treatment. Participants will receive camrelizumab SHR-1210 at a dose of 200 mg every two weeks. Each four-week period counts as one treatment cycle. This phase 2 study explores the impact of camrelizumab on tumor response in patients with recurrent PCNSL. Treatment continues as scheduled, focusing on how well the drug works and its safety profile. During the study, patients will be monitored for their tumor response using MRI scans and assessed for overall health status, side effects, and survival measures. Researchers will track the objective response rate, progression-free survival, overall survival, adverse events, and performance status using the Karnofsky scale over a period of up to three years. Participants will also undergo regular evaluations to ensure ongoing health and safety throughout the study.
CONDITIONS
Brief Title
Camrelizumab for Patients with Recurrent Primary Central Nervous System Lymphoma (PCNSL)
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
